DIALUNOX supports the US diagnostics company QUIDEL in the fight against the COVID crisis by providing the appropriate device platform for the molecular analysis of SARS-CoV-2 infections.
On December 23, the US diagnostics company Quidel announced that it had received FDA emergency approval for its SARS-CoV-2 assay, which runs on DIALUNOX GmbH's Solana platform. The Solana SARS-CoV-2 Assay is an isothermal test based on Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA) for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal (NP) and nasal (NS) swab samples in people with suspected COVID-19 infection.
The availability of this test on the Solana platform enables users to get results from up to 11 patient samples in less than 30 minutes. This is a huge step forward in the implementation of patient screenings, even in decentralized facilities with limited space, as the Solana system only requires a small footprint of 23 x 20 cm.
DIALUNOX has already delivered more than 2000 Solana devices to its partner Quidel and is now increasing capacities to meet the expected increased demand.
The Solana product fits in perfectly with our vision to enable faster, better decisions where they are needed most.
With the SARS-CoV-2 assay on the Solana platform, the US healthcare system now has an additional powerful tool at its disposal to contain the pandemic and localize new hotspots as early as possible.
